General Information of the Compound
| Compound ID |
CP0036702
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
1-(1H-Indol-4-yloxy)-3-isopropylamino-propan-2-ol
Show/Hide
|
||||||||||||||||||
| Synonyms |
(+-)-Pindolol
(1)-1-(1H-Indol-4-yloxy)-3-(isopropylamino)propan-2-ol
1-((1-Methylethyl)amino)-3-(4-indolyloxy)-2-propanol
1-(1H-Indol-4-yloxy)-3-((1-methylethyl)amino)-2-propanol
1-(1H-Indol-4-yloxy)-3-(isopropylamino)-2-propanol
1-(1H-Indol-4-yloxy)-3-[(1-methylethyl)amino]-2-propanol
1-(1H-indol-4-yloxy)-3-(isopropylamino)propan-2-ol
1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)-propan-2-ol
1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol
1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]propan-2-ol
1-(1H-indol-4-yloxy)-3-[(propan-2-yl)amino]propan-2-ol
1-(Indol-4-yloxy)-3-(isopropylamino)-2-propanol
4-(2-Hydroxy-3-isopropylaminopropoxy)-indole
4-(3-(Isopropylamino)-2-hydroxypropoxy)indole
Betapindol
Betapindol (TN)
Blockin L
Blockin L (TN)
Blocklin
Blocklin L
Blocklin L (TN)
Blocklin-L
Blocklin-L (TN)
Calvisken
Calvisken (TN)
Cardilate (TN)
Carvisken
Carvisken (TN)
DL-4-[2-Hydroxy-3-(isopropylamino)propoxy]indole
DL-LB 46
DL-Pindolol
Decreten
Decreten (TN)
Durapindol
Durapindol (TN)
Glauco-Visken (TN)
Glauco-Viskin
Glauco-visken
LB 46
LB-46
LB46
P 0778
P-6820
Pectobloc
Pectobloc (TN)
Pinbetol
Pinbetol (TN)
Pindolol
Pindolol (JP15/USP/INN)
Pindolol [USAN:INN:BAN:JAN]
Pindololum
Pindololum [INN-Latin]
Prindolol
Prindolol (TN)
Prinodolol
Pynastin
Pynastin (TN)
Visken
Visken (TN)
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C14H20N2O2
|
||||||||||||||||||
| Molecular Weight |
248.326
|
||||||||||||||||||
| Canonical SMILES |
CC(C)NCC(O)COc1cccc2[nH]ccc12
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3
Show/Hide
|
||||||||||||||||||
| InChIKey |
JZQKKSLKJUAGIC-UHFFFAOYSA-N
|
||||||||||||||||||
| CAS |
13523-86-9
21870-06-4
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
| DrugBank ID | |||||||||||||||||||
Map of Molecular Bioactivity Related to the Compound
|
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT00819, 5-hydroxytryptamine receptor 1A
Protein ID: PT01179, Beta-1 adrenergic receptor
Protein ID: PT01494, Beta-2 adrenergic receptor
Protein ID: PT01493, Beta-3 adrenergic receptor
Clinical Information about the Compound